North Star Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

North Star Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Buy	1,105 +2	+0.2%	+$603	0.01%	292
2026 Q1	$365K	Sell	1,103 -2	-0.2%	-$681	0.02%	277
2025 Q4	$439K	Sell	1,105 -200	-15%	-$88.5K	0.02%	251
2025 Q3	$595K	Hold	1,305	–	–	0.02%	220
2025 Q2	$426K	Hold	1,305	–	–	0.02%	242
2025 Q1	$352K	Sell	1,305 -5	-0.4%	-$1.28K	0.02%	244
2024 Q4	$308K	Hold	1,310	–	–	0.01%	258
2024 Q3	$360K	Hold	1,310	–	–	0.02%	243
2024 Q2	$318K	Sell	1,310 -200	-13%	-$31.6K	0.02%	254
2024 Q1	$226K	Sell	1,510 -5	-0.3%	-$834	0.01%	289
2023 Q4	$290K	Hold	1,515	–	–	0.01%	253
2023 Q3	$268K	Hold	1,515	–	–	0.02%	254
2023 Q2	$288K	Sell	1,515 -25	-2%	-$4.96K	0.02%	251
2023 Q1	$308K	Hold	1,540	–	–	0.02%	248
2022 Q4	$366K	Hold	1,540	–	–	0.02%	232
2022 Q3	$308K	Sell	1,540 -500	-25%	-$95.4K	0.02%	232
2022 Q2	$298K	Buy	2,040 +20	+1%	+$2.84K	0.02%	237
2022 Q1	$330K	Hold	2,020	–	–	0.02%	246
2021 Q4	$343K	Hold	2,020	–	–	0.02%	244
2021 Q3	$381K	Buy	2,020 +20	+1%	+$3.75K	0.02%	228
2021 Q2	$339K	Hold	2,000	–	–	0.02%	238
2021 Q1	$282K	Hold	2,000	–	–	0.02%	240
2020 Q4	$260K	Hold	2,000	–	–	0.02%	245
2020 Q3	$291K	Hold	2,000	–	–	0.02%	218
2020 Q2	$296K	Sell	2,000 -1,000	-33%	-$135K	0.02%	213
2020 Q1	$327K	Hold	3,000	–	–	0.03%	197
2019 Q4	$346K	Hold	3,000	–	–	0.02%	227
2019 Q3	$241K	Sell	3,000 -1,000	-25%	-$79.1K	0.02%	250
2019 Q2	$290K	Hold	4,000	–	–	0.02%	240
2019 Q1	$374K	Buy	+4,000	New	+$335K	0.03%	222

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

North Star Asset Management's ALNY Position: Q2 2026 in Review

North Star Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.18% in Q2 2026, buying an estimated $603 and bringing the position to 1,105 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #292.

North Star Asset Management first reported a position in ALNY in Q1 2019 and has held it in 30 quarters since. The position peaked at $595K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

North Star Asset Management held 1,105 shares of Alnylam Pharmaceuticals worth $333K as of Q2 2026.
North Star Asset Management bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
Alnylam Pharmaceuticals made up 0.01% of North Star Asset Management's portfolio in Q2 2026, its #292 holding.
North Star Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
North Star Asset Management's Alnylam Pharmaceuticals position peaked at $595K in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on North Star Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.